J.D. Vance: Wall Street Will Tank Bonds to Sabotage Trump

J.D. Vance just dropped a bombshell: With Trump in office, Wall Street could drive the bond market into a death spiral—and your savings might be the first to get crushed.

Daniel Skovronsky net worth and biography

Daniel Skovronsky Biography and Net Worth

SVP of Eli Lilly and Company

Dan Skovronsky is the chief scientific and medical officer of Eli Lilly and Company. He serves as senior vice president of science and technology and president of Lilly Research Laboratories. He also has responsibility for global business development.

Dan joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals Inc., where he had been CEO since founding the company in 2004. At Lilly, Dan has held various roles, including vice president, tailored therapeutics; vice president, diabetes research; and senior vice president, clinical and product development.

Dan completed his residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania. He received his M.D. from the Perelman School of Medicine, University of Pennsylvania, in 2001 and his Ph.D. in neuroscience from University of Pennsylvania in 2000. Dan earned a Bachelor of Science in molecular biophysics and biochemistry from Yale University in 1994.

How old is Daniel Skovronsky?: Dr. Skovronsky is currently 50 years old. There are 7 older executives and no younger executives at Eli Lilly and Company. The oldest executive at Eli Lilly and Company is Mr. Jeffrey N. Simmons, Senior VP & President of Elanco Animal Health, who is 57 years old. Learn More on Daniel Skovronsky's age.
How do I contact Daniel Skovronsky?: The corporate mailing address for Dr. Skovronsky and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on Daniel Skovronsky's contact information.
Has Daniel Skovronsky been buying or selling shares of Eli Lilly and Company?: Daniel Skovronsky has not been actively trading shares of Eli Lilly and Company over the course of the past ninety days. Most recently, on Thursday, June 14th, Daniel Skovronsky bought 10,000 shares of Eli Lilly and Company stock. The stock was acquired at an average cost of $86.22 per share, with a total value of $862,200.00. Learn More on Daniel Skovronsky's trading history.
Who are Eli Lilly and Company's active insiders?: Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), Michael Harrington (VP), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (EVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.
Are insiders buying or selling shares of Eli Lilly and Company?: In the last year, insiders at the sold shares 26 times. They sold a total of 1,410,659 shares worth more than $1,192,819,015.29. The most recent insider tranaction occured on November, 8th when CAO Donald A Zakrowski sold 900 shares worth more than $723,042.00. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.
Information on this page was last updated on 11/8/2024.

Daniel Skovronsky Insider Trading History at Eli Lilly and Company

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/14/2018	Buy	10,000	$86.22	$862,200.00

Daniel Skovronsky Buying and Selling Activity at Eli Lilly and Company

Eli Lilly and Company Company Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Today's Range

Now: $737.00

$737.00

50 Day Range

MA: $882.65

$745.89

$935.09

2 Week Range

Now: $737.00

$561.65

$972.53

Volume

44,770 shs

Average Volume

3,124,268 shs

Market Capitalization

$699.65 billion

P/E Ratio

79.68

Dividend Yield

0.70%

Beta

0.43

J.D. Vance: Wall Street Will Tank Bonds to Sabotage Trump

From Golden Crest | Ad